Status:
COMPLETED
BOTOX® in the Treatment of Crow's Feet Lines in Japan
Lead Sponsor:
Allergan
Conditions:
Lateral Canthus Rhytides
Crow's Feet Lines
Eligibility:
All Genders
20-64 years
Phase:
PHASE3
Brief Summary
This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) compared to placebo for the treatment of Crow's Feet Lines (Lateral Canthus Rhytides).
Eligibility Criteria
Inclusion
- Moderate to severe Crow's Feet Lines
Exclusion
- Current or previous botulinum toxin treatment of any serotype
- Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis
- Facial laser or light treatment for cosmetic purposes, microdermabrasion, superficial peels, or topical retinoid therapy or hormone cream within 3 months
- Laser treatment or phototherapy of the face for medical purposes, blepharoplasty, brow-lift or related procedure, periorbital permanent make-up, or oral retinoid therapy within one year
- Medium-depth or deep facial peels within 5 years
- Prior facial cosmetic surgery (e.g., prior periorbital surgery, facial lift, periorbital treatment with fillers, implantation or transplantation)
Key Trial Info
Start Date :
January 31 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 7 2014
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT01797081
Start Date
January 31 2013
End Date
July 7 2014
Last Update
April 16 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tokyo, Japan